

MORPHOLOGICAL AND FUNCTIONAL CHANGES OF THE LEFT ATRIUM IN OBESITY

Volkanovska Iljevska Cvetanka¹, Andova Valentina², Georgievska Ismail Ljubica²

¹University Clinic for Endocrinology, Diabetes and Metabolic Disorders, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia

²University Clinic for Cardiology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
e-mail: cvetanka_volkanovska@yahoo.com

Abstract

Obesity-related atrial cardiomyopathy is a clinical entity characterized by a variety of functional and structural abnormalities in the atria's myocardium. This study aimed to investigate the morphological and functional alterations of the left atrium (LA) in overweight and obese subjects.

The study included 56 subjects aged 47±9.6 years, categorized into 4 groups according to their body mass index (BMI): group 1 - overweight (BMI 25-29.9 kg/m²); group 2 - class I obesity (BMI 30-34.9 kg/m²); group 3 - class II obesity (BMI 35-39.9 kg/m²) and group 4 - class III obesity (BMI >40 kg/m²). All subjects underwent two-dimensional (2D) conventional echocardiography and speckle tracking myocardial deformation assessment. Left atrial enlargement (LAE) was registered in all four groups, with an average value of LA diameter 40.0±4.9 mm and LA volume (LAV) indexed to height (LAVh) 35.0 ±7.8 ml. Global longitudinal strain (GLS%) and circumferential strain (GCS%) of LA were lower than reference normal values in all groups. LAV indexed to body surface area (LAVI) correlated with hip circumference (r=0.264; p=0.049), whereas LAVh correlated with waist and hip circumference (r=0.378; p=0.004). Linear regression analysis showed that hip circumference was a predictive factor for increasing LAVI (B=0.114; p=0.049; 95%CI 0.000-0.227) and LAVh (B=0.266; p=0.0001; 95%CI 0.129-0.403).

LAVh is a clinically useful echocardiographic parameter to assess LA size in obese population. A sensitive method for detecting subclinical functional alterations of LA is assessment of its speckle tracking longitudinal strain.

Keywords: obesity-related atrial cardiomyopathy, myocardial deformation, 2D speckle tracking

Introduction

The worldwide increase of obesity prevalence and its relation to cardiovascular diseases has generated scientific interest regarding the effects of obesity on the myocardium. The structure and function of the myocardium in obesity undergo remodelling, which is the fundamental cause of obesity-related cardiomyopathy. Expert consensus from several cardiology associations defines atrial cardiomyopathy (AC) as a combination of structural, contractile, and electrophysiological alterations of the atria that have the potential to cause clinically significant symptoms^[1,2]. The volume and pressure load of the atria, impaired myocyte

function, fat accumulation in the pericardium, atrial interstitial fibrosis, inflammation, and myocardial lipodosis are major contributors to obesity-related AC^[3-14].

Obesity is a risk factor for atrial fibrillation (AF)^[15-19]. Left atrial enlargement (LAE), an echocardiographic marker of remodelling in obesity, is one of the pathophysiological factors contributing to AF^[20-22]. Despite the available treatments, AF is still linked with considerable mortality^[23-26] and it is anticipated that AF incidence will increase in tandem with obesity prevalence. Obesity affects LA function as well. In the initial stages of obesity, the LA's reservoir function is reduced, whereas its pump function declines in the later stages of obesity^[27-29].

Studies in obese pediatric population demonstrated that myocardial alterations are prevalent even in the early stages of obesity^[21,30]. However, there are optimistic evidences that weight loss may reverse cardiac abnormalities^[31-36]. We present 56 obese patients in whom we assessed the size of the LA using a two-dimensional (2D) conventional echocardiography and we evaluated the function through myocardial deformation of the LA using the 2D Speckle tracking technique.

Material and methods

Study population

Echocardiographic evaluation underwent 56 obese patients aged 47.7±9.6, who fulfilled the following inclusion criteria for the study: age >18 years; a body mass index of >25 kg/m²; and a history of obesity for more than one year. Exclusion criteria in the selection were the presence of: kidney failure (creatinine clearance eGFR<60 ml/min), lung disease (asthma and/or chronic obstructive pulmonary disease), valvular heart disease, coronary artery disease (previously diagnosed with coronary angiography) and hemoglobinopathies.

After a clinical and metabolic examination at the University Clinic for Endocrinology, Diabetes, and Metabolic Disorders, subjects underwent transthoracic echocardiographic evaluation at the University Clinic for Cardiology in Skopje, North Macedonia.

Subject parameters including age, sex, height, and weight were assessed. Body mass index (BMI) was determined by dividing the weight in kilograms by height in meters squared. According to the World Health Organization's categorization, patients were classified into four groups: overweight (BMI 25-29.9 kg/m²), class I obesity (BMI 30-34.9 kg/m²); class II obesity BMI (35-39.9 kg/m²), and class III obesity (BMI> 40 kg/m²). In addition, anthropometric measures representing visceral obesity, such as waist circumference (high risk >102 cm in males and >88 cm in females) and waist-to-hip circumference ratio, were assessed in the patients. The diagnosis of arterial hypertension was established by measuring systolic blood pressure at 140 mm Hg or diastolic blood pressure at 90 mmHg on two occasions and by collecting data on antihypertensive drug use. A questionnaire was also provided to the patients to assess the presence of obesity-related disorders such as arterial hypertension, type 2 diabetes mellitus, polycystic ovarian syndrome, obstructive sleep apnea, coronary artery disease, peripheral artery disease, and osteoarthritis. All patients underwent a 12-channel electrocardiogram (ECG) to identify who was suitable for sinus rhythm echocardiography.

Echocardiography

Experienced operators performed transthoracic echocardiography using commercially available echocardiographs (GE, Vivid 7) in accordance with the current recommendations of the American Society of Echocardiography^[38,39] and a standardized protocol. To limit interobserver variability, a single cardiologist analyzed all tracings. A special software was

used for offline analysis (EchoPAC PC 08; GE Healthcare). A speckle tracking software was used to evaluate the deformation in accordance with the relevant guidelines of the professional associations.

The maximum value for left atrial volume (LAV) was calculated using the area-length approach and the LA area in 4- and 2-chamber views, as well as the shortest of the two LA long axes measured in the apical 2- and 4-chamber views (ellipsoid model). Thereafter, LAV was indexed to BSA and height. Left atrial enlargement (LAE) was defined: 1. male >35.7 mL/m and female >33.7 mL/m; and LAV indexed to height (LAVh) according to established reference value. LA ejection fraction (LPEF%) was calculated in percentage as the difference between maximal and minimal LAV divided by maximal LAV and multiplied by 100. Using PW Doppler, both velocity in early diastole (E-wave) and velocity in late diastole (A-wave) of the transmitral flow were determined in an apical 4-cavity segment. The velocity of movement of the mitral annulus in a 4-cavity apical segment was measured using tissue Doppler in early diastole (e') and late diastole (a') (TDI). Measures were taken at the lateral and interventricular walls, and an average of both measurements was calculated. The ratio E/e', which represents the mean pressure in the left ventricle (LV) and the pressure of the LV filling, was determined as a derived index. Peak atrial longitudinal strain (PALS), measured at the end of the reservoir phase, and peak atrial contraction strain (PACS), measured just before the start of the active atrial contraction phase, were calculated by averaging the values observed in all accepted LA segments^[40]. The median normal value for global PALS was $\geq 39\%$ and for global PACS $\geq 16\%$ ^[41-42].

Statistical analysis

Categorical parameters were summarized as percentages and continuous parameters as a mean \pm standard deviation (SD). The difference between groups was tested using Pearson's Chi-square test for categorical variables and two-tailed test for continuous variables. Assessment of correlation was done by using the Pearson's correlation analysis. Multiple linear and/or logistic regression analyses were done using clinical and echocardiographic characteristics to identify independent predictors of echocardiographic changes. All data analyses were performed by using SPSS, version 25.0 (IBM SPSS, Inc., Chicago, Illinois, USA), and $p \leq 0.05$ was considered as statistically significant.

Results

Our study included 56 subjects, aged 47 ± 9.6 years, with a larger number of female subjects (Table 1). The investigated group's average body weight was 34.6 kg/m². The predominant subjects' risk factors for cardiovascular disease were hypertension, dyslipidemia, and diabetes. According to BMI, subjects were categorized into four groups. Subjects' distribution is shown in Table 2. There were 36 women among the total number of participants, with a higher average age, BMI, and hip circumference than men (Table 3). Table 4 displays the LA measurements in the four groups of subjects. According to the analysis, the mean values of the LA dimensions and the LAVh increased as the weight increased, while the LAVI did not. PALS values for the longitudinal deformation of the LA during the time when LA functions as a reservoir were below the reference normal values for all four groups of patients (Table 4). Regarding PACS, values were lower, particularly for classes 2 and 3 of obesity. Cross-comparison revealed that groups did not differ statistically substantially in terms of LA size and function. Table 5 shows the correlation analysis. Higher BMI was not linked with normalized volume for either body surface area or height but was statistically substantially associated with higher LA dimension and volume. Furthermore, higher BMI was significantly associated with increased LAEF (%). Greater waist circumference was statistically significantly correlated with greater LA dimension, LA

volume, and LAVh, but not with LAVI. Likewise, waist circumference correlated positively with the left ventricular ejection fraction (%), and it was the only variable that correlated with the left ventricular mass index (LVMi). Hip circumference correlated statistically with LA dimension, LA volume, LAVI, LAVh, and LAEF (%). Waist-to-hip ratio was shown to have a single significant relationship with LA dimension.

Table 1. Baseline characteristics of 56 subjects

Age at echo (y)	47.7 ± 9.6
Sex male (%) / female (%)	20 (35.7)/36 (64.3)
BMI (kg/m²)	34.6 ± 5.1
Waist circumference (cm)	113.2 ± 14.2
Hip circumference (cm)	120.4 ± 13.7
Waist/hip ratio (cm)	0.93 ± 0.07
Hypertension (%)	44.6
Dyslipidaemia (%)	39.3
Diabetes (%)	33.3

BMI-body mass index (kg/m²)

Table 2. Percentage representation of obesity class

	Frequency	Percentage
Overweight	9	16.1
Class I obesity	26	46.4
Class II obesity	13	23.2
Class III obesity	8	14.3

Table 3. Baseline characteristics of 56 subjects divided by gender

	Male n=20	Female n=36
Age (years)	46.3 ± 8.4	48.5 ± 10.1
BMI (kg/m²)	33.9 ± 4.8	34.9 ± 5.3
Waist circumference (cm)	116.4 ± 11.6	111.4 ± 15.3
Hip circumference (cm)	117.5 ± 12.4	122.1 ± 14.3
Ratio waist/hip (cm)	0.97 ± 0.05	0.91 ± 0.07

Table 4. Echocardiographic morphological and functional parameters of left atrium and left ventricle in 56 subjects categorized by BMI

	Overweight n=9	Class I obesity n=26	Class II obesity n=13	Class III obesity n=8	p
Age (years)	46.5 ± 9.0	48.8 ± 11.1	47.2 ± 7.7	46.3 ± 8.3	0.888
Sex m/f (%)	33.3/66.7	38.5/61.5	30.8/69.2	37.5/62.5	0.968
Waist circumference (cm)	99.0 ± 8.9	109.8 ± 11.7	120.0 ± 9.9	129.1 ± 12.8	0.0001 Owt vs. Class II & Class III Class I vs. Class III
Hip circumference (cm)	104.6 ± 4.2	117.9 ± 10.9	125.2 ± 10.3	138.7 ± 9.1	0.0001 Owt vs. Class I.

						II & III Class I vs. class III
Ratio waist/hip (cm)	0.94 ± 0.09	0.93 ± 0.06	0.96 ± 0.07	0.92 ± 0.08		0.629
LA dimension (mm)	37.1 ± 5.3	39.6 ± 3.8	41.0 ± 5.2	42.7 ± 6.2		0.096
LAV (ml)	56.5 ± 13.9	56.5 ± 10.0	62.2 ± 18.6	69.6 ± 13.4		0.095
LAVI (ml/m ²)	28.7 ± 5.6	27.7 ± 5.2	27.9 ± 7.6	29.5 ± 6.2		0.896
LAVh (ml/m)	33.0 ± 7.0	33.3 ± 6.0	35.9 ± 9.8	35.0 ± 7.8		0.083
LAef (%)	40.6 ± 12.0	46.2 ± 8.5	50.5 ± 11.2	49.4 ± 8.0		0.115
e' septum (cm/s)	7.8 ± 2.5	6.9 ± 1.9	7.3 ± 1.9	8.8 ± 2.5		0.155
e' lateral (cm/s)	11.4 ± 4.1	9.2 ± 3.5	11.4 ± 3.2	10.7 ± 2.5		0.184
e' percentage (cm/s)	9.6 ± 3.1	8.2 ± 2.8	9.4 ± 2.0	9.8 ± 2.1		0.309
E/e' septum	10.7 ± 3.1	12.0 ± 3.1	11.7 ± 3.5	10.7 ± 2.9		0.637
E/e' lateral	7.6 ± 2.6	9.5 ± 3.0	7.8 ± 3.1	8.8 ± 2.7		0.252
E/e' percentage	8.8 ± 2.3	10.5 ± 2.5	9.2 ± 3.0	9.8 ± 2.6		0.285
PALS (%)	31.1 ± 4.2	29.2 ± 11.4	30.3 ± 7.9	28.4 ± 5.2		0.928
PACS (%)	15.9 ± 3.7	16.6 ± 6.1	17.2 ± 7.3	14.0 ± 3.8		0.700
LVMi	82.0 ± 24.9	99.0 ± 23.8	95.3 ± 24.9	86.2 ± 27.6		0.278
RWT	0.39 ± 0.05	0.44 ± 0.09	0.43 ± 0.09	0.41 ± 0.09		0.457

LAEF: left atrial ejection fraction; LAV=left atrial volume LAVI=left atrial volume indexed to BSA; LAV_h= left atrial enlargement indexed to height; e': tissue velocity measured at the level of the mitral annulus in early diastole with Tissue Doppler; E/e' = ratio between the early diastolic transmitral flow and the speed of movement of the mitral ring in early diastole determined by tissue Doppler; PALS=peak atrial longitudinal strain; PACS=peak atrial contraction strain; s'TDI; LVMi:LV mass indexed; RWT: relative wall thickness

Table 5. Correlations of anthropometric parameters with parameters of LA size and function

	BMI (kg/m ²)	Waist circumference (cm)	Hip circumference (cm)	Ratio waist/hip
LA dimension (mm)	r=0.331; p=0.013	r=0.473; p=0.0001	r=0.244; p=0.070	r=0.352; p=0.008
LAV (ml)	r=0.310; p=0.020	r=0.451; p=0.001	r=0.469; p=0.0001	-
LAVI (ml/m ²)	-	-	r=0.264; p=0.049	-
LAVh (ml/m)	-	r=0.378; p=0.004	r=0.469; p=0.0001	-
LAef (%)	r=0.283; p=0.035	r=0.271; p=0.043	r=0.310; p=0.020	-
LVMi	-	r=0.231; p=0.087	-	-

LAEF: left atrial ejection fraction; LAV=left atrial volume LAVI=left atrial volume indexed to BSA; LAV_h= left atrial enlargement indexed to height; p-value < 0.05 statistical significance r = Pearson correlation coefficient

To determine the role of obesity and its expression parameters (BMI, waist circumference, hip circumference, and their ratio) as independent predictive factors in the occurrence of echocardiographic changes in the morphology and function of the LA, we performed a linear regression analysis with the obesity variables normalized for age and sex. The analysis showed that hip circumference was an independent predictor of increasing maximal LAV (B=0.476; p=0.0001; 95%CI 0.231-0.721) (Figure 1A), LAVI (B=0.114; p=0.049; 95%CI 0.000-0.227) (Figure 1B), and LAVh (B=0.266; p=0.0001; 95%CI 0.129-0.403) (Figure 1C). Accordingly, an increase of nearly 0.5% in hip circumference results in an increase of one unit ml in maximal LAV, an increase of nearly 0.1% in hip circumference increases maximal LAVI by one unit ml, and an increase of nearly 0.3% in hip circumference increases maximal LAVh by one unit ml.




Fig. 1. A graphic illustration of the effect of hip circumference as a predictor of increased peak LA volume (A), LAVI (B), and LAVh (C)

Reproducibility

In order to assess the reproducibility as well as reliability of LA strain measurements, we calculated the intra-class correlation coefficient (ICC) by assessing 20 randomly selected images seen in two different occasions by the same investigator. The Intraclass Correlation Coefficient (ICC) for LA strain measurements was 0.911 (95% CI 0.739-0.970).

Discussion

Obesity is a significant etiological factor in atrial remodeling^[43]. Atrial remodeling is the underlying cause of atrial cardiomyopathy (AP), which has recently been defined by a consensus of several cardiology societies as a combination of structural, contractile, and electrophysiological alterations of the atria that have a potential to cause clinically relevant manifestations^[1]. Enlargement of the LA is a clinical hallmark of structural remodeling caused by volume and pressure load of the LA; accordingly, LAV is a reliable biomarker for evaluation of diastolic dysfunction^[44].

Comparative studies have demonstrated that obese and overweight people have greater LA dimensions and volumes than people of normal weight^[45-47]. Also, these studies have demonstrated that there is a dose-dependent relationship between BMI and LAE. Our findings are in line with the data presented in the literature. Left atrial dimensions were increased in all categories of obesity. Regarding volume values, we observed increased values for volume when was indexed for height, but not when indexed for body surface area. Left atrial enlargement is a physiological adaptation process conditioned by an increased intravascular and stroke volume, which occurs in response to the metabolically active adipose tissue requirements. However, at the same time, LAE in obesity may be pathogenic as a result of several factors including pressure load on the LA (diastolic dysfunction and LV

hypertrophy), effects of adipose tissue mediators and fatty acids and the activation of various neurohormonal pathways^[3-14]. Therefore, LAV is not an appropriate marker as it does not distinguish between these two forms of remodeling. According to Aiad *et al.*^[49], LAE in obesity should be considered in the context of left ventricular (LV) remodeling rather than just as absolute volume. In their study, they showed that LAE in obese subjects was proportionate to LV enlargement and associated with eccentric remodeling^[49]. A LAE disproportionate to LV was related to increased LV mass and thickness of LV's posterior wall. Aside from the hemodynamic factors, it is crucial to highlight that LAE is prevalent in obese population even when there is no associated cardiovascular disease or diastolic dysfunction^[49].

The use of anthropometric measures to index LA allows for the differentiation of normal from pathological LAE. Left atrium increases in parallel with an increase in body dimensions. However, the link between heart and body size is not linear, and they do not increase in parallel^[50]. The isometric indexing of LA volume with body surface area is the most commonly used metric method^[51], but it underestimates the effect of obesity on LA. An allometric model that indexes LA to height has a dose-dependent relationship with BMI, E/E', and comorbidities and best depicts LAE in obesity^[52-53]. Furthermore, height is correlated with metabolic adipose tissue. Our analysis appear to support these studies. As BMI increased, LAV volume indexed for height increased, however LAV indexed for body surface area did not.

Several studies indicate that BMI may predict LAE^[46,48,55-56]. The study conducted by Ayer *et al.*^[46] on 2042 obese patients revealed that BMI was a strong and independent predictor of LAE. Likewise, McManus *et al.*^[55] during a 16-year follow-up of 4403 individuals discovered a positive correlation between LA dimensions and several factors, including BMI. Age, male gender, systolic blood pressure, and antihypertensive medication all showed out as important variables in this study^[55]. Another prospective study^[56] investigating the variables that affect LA remodeling over aging found that obesity was the most powerful predictor of LAE, even outperforming arterial hypertension statistically^[56]. Posterior wall thickness of LV, dimensions and function of LV, age, and gender also were independent predictors of LAE^[46,48]. A correlation between BMI and LAE was established in our study and hip circumference appeared as a predictor of increased LAV, LAVI and LAVh.

Because LAV represents the long-term hemodynamic alterations to which LA is exposed, it cannot be used to identify LA remodeling in the early stages of obesity. The phase function of LA is an echocardiographic parameter that is becoming important in echocardiographic practice as alterations in LA function may precede structural LA remodeling^[57]. Furthermore, several studies have shown that LA function is an important cardiovascular prognostic marker^[28,59]. Myocardial deformation of LA during the period when the LA function as a reservoir (PALS) is the first to be altered by obesity^[54]. Studies have demonstrated an inverse relationship between PALS and BMI^[27,58]. The pump function of LA, presented by PACS, is initially increased as a compensatory response, but it gradually declines^[58]. A deterioration in pump function is thought to have a crucial role in the development of heart failure in obesity^[27,58,59]. In our analysis, we found lower values for PALS and PACS. This might be a result of a longer duration of obesity in our patients.

Conclusion

According to our findings, we conclude that 2D speckle tracking is a sensitive method for detecting subclinical myocardial alterations. The findings of myocardial deformation method might have a substantial impact on current clinical practice. The method of atrial speckle tracking is an eligible screening tool that deserves to be used in clinical practice,

because timely diagnosis of obesity-related atrial cardiomyopathy enables active promotion and timely implementation of therapeutic measures to protect cardiovascular health.

Conflict of interest statement. None declared.

References

1. Goette A, Kalman JM, Aguinaga L, Cabrera JA, Chen SA, Chugh SS, et al. EHRA/HRS/APHS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. *Europace* 2016; 18(10):1455-1490. doi:10.1093/europace/euw161.
2. Hatem SN, Redheuil A, Gandjbakhch E. Cardiac adipose tissue and atrial fibrillation: the perils of adiposity. *Cardiovasc Res* 2016; 109(4):502-509. doi: 10.1093/cvr/cvw001.
3. Mahabadi AA, Lehmann N, Kalsch H, Bauer M, Dykun I, Kara K, et al. Association of epicardial adipose tissue and left atrial size on non-contrast CT with atrial fibrillation: the Heinz Nixdorf Recall Study. *Eur Heart J Cardiovasc Imaging* 2014; 15(8):863-869. doi: 10.1093/ehjci/jeu006.
4. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. *J Mol Med* 2001; 79:21-29. doi:10.1007/s001090000 144.
5. Hirsh BJ, Copeland-Halperin RS, Halperin J L. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: Mechanistic links and clinical inferences. *J Am Coll Cardiol* 2015; 65:2239-2251. doi: 10.1016/j.jacc.2015.03.557.
6. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. *Proc Natl Acad Sci U S A* 2000; 97(4):1784-1789. doi:10.1073/pnas.97.4.1784.
7. Vincent HK, Powers SK, Stewart DJ, Shanely RA, Demirel H, Naito H. Obesity is associated with increased myocardial oxidative stress. *Int J Obes Relat Metab Disord* 1999; 23:67-74. doi: 10.1038/sj.ijo.0800761.
8. Ybarra J, Resmini E, Planas F, Navarro-Lopez F, Webb S, Pou JM, et al. Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart. *Obes Surg* 2009; 19:1324-1332. doi: 10.1007/s11695-00 9-9924-5.
9. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, Frohlich ED. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. *Arch Intern Med* 1981; 141(1):81-85. doi: 10.1001/archinte.141.1.81.
10. Messerli F, Ventura H, Reisin E, Dreslinski G, Dunn F, Macphee A, Frohlich E. Borderline Hypertension and Obesity: Two Prehypertensive States with Elevated Cardiac Output. *Circulation* 1982; 66:55-60. doi: 10.1001/archinte.141.1.81.
11. Selvaraj S, Martinez EE, Aguilar FG, Kim KY, Peng J, Sha J, et al. Association of Central Adiposity with Adverse Cardiac Mechanics: Findings from the Hypertension Genetic Epidemiology Network Study. *Circ Cardiovasc Imaging* 2016; 9(6): 10.1161/CIRCIMAGING. 115.004396 e004396. doi:10.1161/CIRCIMAGING.115.004396.
12. Iacobellis G, Ribaldo MC, Leto G, Zappaterreno A, Vecchi E, Di Mario U, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. *Obes Res* 2002; 10:767-773. doi:10.1038/oby.2002.104.
13. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, et al. Diastolic dysfunction and left atrial volume: a population-based study. *J Am Coll Cardiol* 2005; 45(1):87-92. doi: 10.1016/j.jacc.2004.09.054.

14. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. *Circulation* 2005; 112(21):3247-3255. doi: 10.1161/CIRCULATIONAHA.105.553743.
15. Foy AJ, Mandrola J, Liu G, Naccarelli GV. Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults. *Am J Cardiol* 2018; 121(9):1072-1075. doi: 10.1016/j.amjcard.2018.01.019.
16. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. *JAMA* 2004; 292(20):2471-7. doi: 10.1001/jama.292.20.2471.
17. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. *Eur Heart J* 2008; 29(18):2227-2233. doi:10.1093/eurheartj/ehn324.
18. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *J Am Coll Cardiol* 2007; 49:565-571. doi: 10.1016/j.jacc.2006.08.060.
19. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial size: physiologic determinants and clinical applications. *J Am Coll Cardiol* 2006; 47:2357-2363. doi: 10.1016/j.jacc.2006.02.048.
20. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. *Mayo Clin Proc* 2001; 76(5):467-475. doi: 10.4065/76.5.467.
21. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. *J Am Coll Cardiol* 2003; 42(7):1206-1207. doi: 10.1016/s0735-1097(03)00956-2.
22. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolfe PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. *Circulation* 1995; 92(4):835-841. doi: 10.1161/01.cir.92.4.835.
23. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. *Stroke* 1999; 30(10):2019-2024. doi: 10.1161/01.str.30.10.2019.
24. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, et al. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. *Mayo Clin Proc* 2004; 79(8):1008-1014. doi:10.4065/79.8.1008.
25. Takemoto Y, Barnes ME, Seward JB, Lester SJ, Appleton CA, Gersh BJ, et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. *Am J Cardiol* 2005; 96(6):832-836. doi: 10.1016/j.amjcard.2005.05.031.
26. Abou R, Leung M, Tonsbeek AM, Podlesnikar T, Maan AC, Schali MJ, et al. Effect of Aging on Left Atrial Compliance and Electromechanical Properties in Subjects Without Structural Heart Disease. *Am J Cardiol* 2017; 120:140-147. doi: 10.1016/j.amjcard.2017.03.243.
27. Ramkumar S, Yang H, Wang Y, Nolan M, Negishi T, Negishi K, et al. Association of the Active and Passive Components of Left Atrial Deformation with Left Ventricular Function. *J Am Soc Echocardiogr* 2017; 30(7):659-666. doi: 10.1016/j.echo.2017.03.014.
28. Habibi M, Chahal H, Opdahl A, Gjesdal O, Helle-Valle TM, Heckbert SR, et al. Association of CMR-measured LA function with heart failure development: results from the MESA study. *JACC Cardiovasc Imaging* 2014; 7: 570-579. doi: 10.1016/j.jcmg.2014.01.016.

29. Di Salvo G, Pacileo G, Del Giudice EM, Natale F, Limongelli G, Verrengia M, et al. Abnormal myocardial deformation properties in obese, non-hypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. *Eur Heart J* 2006; 27: 2689-2695. doi:10.1093/eurheartj/ehl163.
30. Di Salvo G, Pacileo G, Del Giudice EM, Natale F, Limongelli G, Verrengia M, et al. Atrial myocardial deformation properties in obese nonhypertensive children. *J Am Soc Echocardiogr* 2008; 21(2): 151-156. doi: 10.1016/j.echo.2007.05.028.
31. Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. *Obesity (Silver Spring)* 2008; 16(7): 1693-1697. doi:10.1038/oby.2008.251.
32. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. *Am Heart J* 1996; 131(2): 313-319. doi:10.1016/s0002-8703(96)90360-9.
33. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. *Am J Cardiol* 1985; 55(6): 783-786. doi:10.1016/0002-9149(85)90156-0.
34. Karason K, Wallentin I, Larsson B, Sjoström L. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. *BMJ* 1997; 315(7113): 912-916. doi: 10.1136/bmj.315.7113.912.
35. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. *Am J Cardiol*. 1995;76(16):1194-1197. doi:10.1016/s0002-9149(99)80338-5
36. Owan T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, et al. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. *J Am Coll Cardiol* 2011; 57(6): 732-739. doi: 10.1016/j.jacc.2010.10.017.
37. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. *Obes Res* 1998; 6(Suppl 2): 51S-209S.
38. Lang RM, Badano LP, Mor-Avi V, Afzalpoor J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015; 28(1): 1-39. doi: 10.1016/j.echo.2014.10.003.
39. Pathan F, D'Elia N, Nolan MT, Marwick TH, Negishi K. Normal Ranges of Left Atrial Strain by Speckle-Tracking Echocardiography: A Systematic Review and Meta-Analysis. *J Am Soc Echocardiogr* 2017; 30(1): 59-70.e8. doi: 10.1016/j.echo.2016.09.007.
40. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, et al. Obesity results in progressive atria structural and electrical remodeling: implications for atrial fibrillation. *Heart Rhythm* 2013; 10(1): 90-100. doi:10.1016/j.hrthm.2012.08.043.
41. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *Am J Cardiol* 2002; 90(12): 1284-1289. doi:10.1016/s0002-9149(02)02864-3.
42. Huang G, Parikh PB, Malhotra A, Gruberg L, Kort S. Relation of Body Mass Index and Gender to Left Atrial Size and Atrial Fibrillation. *Am J Cardiol* 2017; 120(2): 218-222. doi: 10.1016/j.amjcard.2017.04.013.

43. Ayer JG, Almafragy HS, Patel AA, Hellyer RL, Celermajer DS. Body mass index is an independent determinant of left atrial size. *Heart Lung Circ* 2008; 17(1): 19-24. doi: 10.1016/j.hlc.2007.04.006.
44. Gottdiener JS, Reda DJ, Williams DW, Materson BJ. Left atrial size in hypertensive men: influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *J Am Coll Cardiol* 1997; 29(3): 651-658. doi:10.1016/s0735-1097(96)00554-2.
45. Kumar P, Mundi A, Caldito G, Reddy P. Higher Body Mass Index is an Independent Predictor of Left Atrial Enlargement. *International Journal of Clinical Medicine* 2011; 2(5): 556-560. doi:10.4236/ijcm.2011.25091.
46. Aiad NN, Hearon C Jr, Hieda M, Dias K, Levine BD, Sarma S. Mechanisms of Left Atrial Enlargement in Obesity. *Am J Cardiol* 2019; 124(3): 442-447. doi: 10.1016/j.amjcard.2019.04.043.
47. Batterham AM, George KP, Whyte G, Sharma S, McKenna W. Scaling cardiac structural data by body dimensions: a review of theory, practice, and problems. *Int J Sports Med* 1999; 20(8): 495-502. doi:10.1055/s-1999-8844.
48. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005; 18(12): 1440-1463. doi:10.1016/j.echo.2005.10.005.
49. Yao GH, Vallurupalli N, Cui J, Hiser WL, Cook JR, Jiang L. Allometric model improves scaling of left atrial size in obese population: the use of body weight containing variables is challenged. *Echocardiography* 2011; 28(3): 253-260. doi:10.1111/j.1540-8175.2010.01337.x.
50. 16. Airale L, Paini A, Ianniello E, Mancusi C, Moreo A, Gaudo G, et al. Left atrial volume indexed for height² is a new sensitive marker for subclinical cardiac organ damage in female hypertensive patients. *Hypertens Res.* 2021; 44: 1-8. Jeyaprakash P, Moussad A, Pathan S, et al. A Systematic Review of Scaling Left Atrial Size: Are Alternative Indexation Methods Required for an Increasingly Obese Population?. *J Am Soc Echocardiogr.* 2021;34(10):1067-1076.e3. doi:10.1016/j.echo.2021.05.009
51. Heymsfield SB, Gallagher D, Mayer L, Beetsch J, Pietrobelli A. Scaling of human body composition to stature: new insights into body mass index. *Am J Clin Nutr* 2007; 86(1): 82-91. doi: 10.1093/ajcn/86.1.82.
52. McManus DD, Xanthakis V, Sullivan LM, Zachariah J, Aragam J, Larson MG, et al. Longitudinal tracking of left atrial diameter over the adult life course: Clinical correlates in the community. *Circulation* 2010; 121(5): 667-674. doi: 10.1161/CIRCULATIONAHA.109.885806.
53. Stritzke J, Markus MR, Duderstadt S, Lieb W, Luchner A, Döring A, et al. MONICA/KORA Investigators. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J Am Coll Cardiol* 2009; 54(21): 1982-1989. doi: 10.1016/j.jacc.2009.07.034.
54. Jarasunas J, Aidietis A, Aidietiene S. Left atrial strain-an early marker of left ventricular diastolic dysfunction in patients with hypertension and paroxysmal atrial fibrillation. *Cardiovasc Ultrasound* 2018; 16(1): 29. doi: 10.1186/s12947-018-0147-6.

55. Chirinos JA, Sardana M, Satija V, Gillebert TC, De Buyzere ML, Chahwala J, et al. Asklepios investigators. Effect of Obesity on Left Atrial Strain in Persons Aged 35-55 Years (The Asklepios Study). *Am J Cardiol* 2019; 123(5): 854-861. doi: 10.1016/j.amjcard.2018.11.035.
56. Ramkumar S, Yang H, Wang Y, Nolan M, Negishi T, Negishi K, et al. Association of the Active and Passive Components of Left Atrial Deformation with Left Ventricular Function. *J Am Soc Echocardiogr* 2017; 30(7): 659-666. doi: 10.1016/j.echo.2017.03.014.
57. Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, et al. Left atrial structure and function and clinical outcomes in the general population. *Eur Heart J* 2013; 34(4): 278-285. doi.org/10.1093/eurheartj/ehs188.
58. Habibi M, Samiei S, Ambale Venkatesh B, Opdahl A, Helle-Valle TM, Zareian M, et al. Cardiac Magnetic Resonance-Measured Left Atrial Volume and Function and Incident Atrial Fibrillation: Results from MESA (Multi-Ethnic Study of Atherosclerosis). *Circ Cardiovasc Imaging* 2016; 9(8): 10.1161/CIRCIMAGING.115.004299 e004299. doi: 10.1161/CIRCIMAGING.115.004299.
59. Chinali M, de Simone G, Roman MJ, Bella JN, Liu JE, Lee ET, et al. Left atrial systolic force and cardiovascular outcome. The Strong Heart Study. *Am J Hypertens* 2005; 18(12 Pt 1): 1570-1577. doi: 10.1016/j.amjhyper.2005.05.036.